BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 23714157)

  • 1. Challenges in cancer vaccine development for hepatocellular carcinoma.
    Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
    J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial immunotherapy strategies for hepatocellular carcinoma.
    Tagliamonte M; Petrizzo A; Tornesello ML; Ciliberto G; Buonaguro FM; Buonaguro L
    Curr Opin Immunol; 2016 Apr; 39():103-13. PubMed ID: 26851637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
    Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
    Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer vaccines for hepatocellular carcinoma: future directions.
    Buonaguro FM; Buonaguro L
    Immunotherapy; 2016; 8(4):391-3. PubMed ID: 26973120
    [No Abstract]   [Full Text] [Related]  

  • 5. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
    Marotta F; Vangieri B; Cecere A; Gattoni A
    Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model.
    Tagliamonte M; Petrizzo A; Napolitano M; Luciano A; Arra C; Maiolino P; Izzo F; Tornesello ML; Aurisicchio L; Ciliberto G; Buonaguro FM; Buonaguro L
    Cancer Immunol Immunother; 2015 Oct; 64(10):1305-14. PubMed ID: 25944003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of immunotherapy for hepatocellular carcinoma.
    Breous E; Thimme R
    J Hepatol; 2011 Apr; 54(4):830-4. PubMed ID: 21145836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
    Schmidt N; Neumann-Haefelin C; Thimme R
    Dig Dis; 2012; 30(5):483-91. PubMed ID: 23108304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
    Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Petrizzo A; Buonaguro L
    Cancer Lett; 2020 Mar; 473():25-32. PubMed ID: 31875523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HEPATOCELLULAR CARCINOMA: CURRENT AND PROSPECTIVE IMMUNOTHERAPEUTIC STRATEGIES.
    Kikodze N; Mazmishvili K; Iobadze M; Rekhviashvili Kh; Nanava N; Pantsulaia I; Mizandari M; Janikashvili N; Chikovani T
    Georgian Med News; 2015 Sep; (246):78-84. PubMed ID: 26355320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.
    Fatourou EM; Koskinas JS
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1499-510. PubMed ID: 19828011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for hepatocellular carcinoma.
    Li S; Yang F; Ren X
    Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
    Sawada Y; Nakatsura T
    Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma: systemic therapies and future perspectives.
    Mikhail S; Cosgrove D; Zeidan A
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1205-18. PubMed ID: 25199765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma.
    Seifi-Alan M; Shamsi R; Ghafouri-Fard S
    Immunotherapy; 2018 Apr; 10(5):411-421. PubMed ID: 29473472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma.
    Wang Q; Luan W; Warren L; Kadri H; Kim KW; Goz V; Blank S; Isabel Fiel M; Hiotis SP
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):574-582. PubMed ID: 26786094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives of immunotherapy in hepatocellular carcinoma (HCC).
    Büttner N; Schmidt N; Thimme R
    Z Gastroenterol; 2016 Dec; 54(12):1334-1342. PubMed ID: 27936483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma.
    Chen Y; Yang D; Li S; Gao Y; Jiang R; Deng L; Frankel FR; Sun B
    Oncogene; 2012 Apr; 31(17):2140-52. PubMed ID: 21927025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.